← Leaderboards
George Z Retsch-Bogart
University Of North Carolina Chapel Hill
$110,398
Attributed
$110,398
Total exposure
16
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $36.1K · FY2005–08$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$110,398 · 16
By mechanism
M01$110,398 · 16
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Scott H Donaldson$8,054,486
- Michael R Knowles$33,731,453
- David B Peden$24,843,616
- Raymond J Pickles$6,417,208
- Ray C Williams$233,569
Research focus
Computer Retrieval Of Information On Scientific Projects DatabaseFundingSafetyUnited States National Institutes Of HealthResearch PersonnelSourceResourcesInstitutionGrantCystic FibrosisClinical Trials, Phase IiiClinical TrialsDoseCystic Fibrosis PatientsPatient Oriented ResearchHuman Therapy EvaluationLabelHuman SubjectPlacebosClinical ResearchBreathingPseudomonas AeruginosaMetabolism Disorder ChemotherapyEnd Point
Grant awards (20)
CLINICAL TRIAL: DENUFOSOL TETRASODIUM INHALATION SOLUTION IN PATIENTS WITH MILD$3,290
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE III - MULTIPLE COURSES OF AZTREONAM LYSINATE FOR INHALATIO$842
M01 · FY2008 · RR · contact PI
EPIC CLINICAL TRIAL: PSEUDOMONAS AERUGINOSA AIRWAY INFECTION IN YOUNG CF PATIEN$76
M01 · FY2008 · RR · contact PI
DENUFOSOL TETRASODIUM INHALATION SOLUTION IN PATIENTS WITH MILD CF$2,814
M01 · FY2007 · RR · contact PI
PHASE III - MULTIPLE COURSES OF AZTREONAM LYSINATE FOR INHALATION IN CF PATIENTS$1,313
M01 · FY2007 · RR · contact PI
EPIC CLINICAL TRIAL: PSEUDOMONAS AERUGINOSA AIRWAY INFECTION IN YOUNG CF PATIEN$938
M01 · FY2007 · RR · contact PI
28-DAY STUDY OF DENUFOSOL TETRASODIUM (INS37217) INHALATION SOLUTION - CF$7,434
M01 · FY2006 · RR · contact PI
INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENTS IN CYSTIC FIBROSIS$1,983
M01 · FY2006 · RR · contact PI
AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS WITH PULMONARY P$1,734
M01 · FY2006 · RR · contact PI
EPIC CLINICAL TRIAL: PSEUDOMONAS AERUGINOSA AIRWAY INFECTION IN YOUNG CF PATIEN$1,487
M01 · FY2006 · RR · contact PI
AZTREONAM FOR INHALATION (AI) IN CYSTIC FIBROSIS PATIENTS WITH LUNG DISEASE$17,593
M01 · FY2005 · RR
24 WEEKS OF ORAL TREATMENT WITH BIIL 284 BS IN ADULT AND PEDIATRIC CF PATIENTS$13,823
M01 · FY2005 · RR
INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENTS IN CYSTIC FIBROSIS$2,514
M01 · FY2005 · RR
28-DAY STUDY OF INS37217 INHALATION SOLUTION IN SUBJECTS WITH CYSTIC FIBROSIS$1,256
M01 · FY2005 · RR
ANTIMICROBIAL TREATMENT EFFECT FOLLOWING ADMIN OF TOBI IN YOUNG CF PATIENTS$629
M01 · FY2005 · RR
ASCENDING SINGLE DOSES OF AZTREONAM FOR INHALATION (AI) IN PATIENTS WITH CF$314
M01 · FY2005 · RR
Ascending Single Doses of Aztreonam for Inhalation (AI) in Patients with CF$29,717
M01 · FY2004 · RR
28-Day Study of INS37217 Inhalation Solution in Subjects with Cystic Fibrosis$16,415
M01 · FY2004 · RR
Antimicrobial Treatment Effect Following Admin. of TOBI in Young CF Patients$3,679
M01 · FY2004 · RR
24 Weeks of Oral Treatment with BIIL 284 BS in Adult and Pediatric CF Patients$2,547
M01 · FY2004 · RR